Moleculin Biotech, Inc. (MBRX)
NASDAQ: MBRX · Real-Time Price · USD
4.290
+0.010 (0.23%)
At close: Jan 30, 2026, 4:00 PM EST
4.162
-0.128 (-2.99%)
After-hours: Jan 30, 2026, 7:16 PM EST
Moleculin Biotech Employees
Moleculin Biotech had 17 employees as of December 31, 2024. The number of employees decreased by 1 or -5.56% compared to the previous year.
Employees
17
Change (1Y)
-1
Growth (1Y)
-5.56%
Revenue / Employee
n/a
Profits / Employee
-$3,024,176
Market Cap
13.21M
Employees Chart
Employees History
| Date | Employees | Change (1Y) | Growth (1Y) | Full-Time | Part-Time |
|---|---|---|---|---|---|
| Dec 31, 2024 | 17 | -1 | -5.56% | 17 | 0 |
| Dec 31, 2023 | 18 | -1 | -5.26% | 18 | 0 |
| Dec 31, 2022 | 19 | 2 | 11.76% | 15 | 4 |
| Dec 31, 2021 | 17 | 2 | 13.33% | 13 | 4 |
| Dec 31, 2020 | 15 | -1 | -6.25% | 10 | 5 |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2015 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Related Stocks
| Company Name | Employees |
|---|---|
| BioLineRx | 28 |
| Longeveron | 25 |
| Tempest Therapeutics | 21 |
| BioCardia | 20 |
| Soligenix | 16 |
| CalciMedica | 15 |
| Sensei Biotherapeutics | 15 |
| Cocrystal Pharma | 11 |
MBRX News
- 19 days ago - Moleculin Reports Independent Assessment Confirms No Cardiotoxicity of Annamycin in 90 Subjects - GlobeNewsWire
- 20 days ago - Moleculin Accelerates Outlook Into 2026 With First Pivotal Trial Unblinding on Track, Global Trial Expansion, and Multiple Externally/IIT Funded Clinical Programs - GlobeNewsWire
- 6 weeks ago - Moleculin Announces Positive Results from Phase 1 Clinical Trial Evaluating WP1066 for the Treatment of Pediatric Recurrent Malignant Brain Tumors - GlobeNewsWire
- 7 weeks ago - Moleculin Announces Exercise of Warrants for $6.8 Million Gross Proceeds - GlobeNewsWire
- 7 weeks ago - Moleculin Announces Completion of Treatment for the 45 Patients in Pivotal “MIRACLE” Phase 3 AML Trial on Pace for Q1 2026 - GlobeNewsWire
- 7 weeks ago - Moleculin Announces New Annamycin Collaboration in Brain Tumors - GlobeNewsWire
- 2 months ago - Moleculin to Participate in the Virtual Investor Closing Bell Series - GlobeNewsWire
- 2 months ago - Moleculin Announces Reverse Stock Split - GlobeNewsWire